Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone

Todd A Davies1, Robert K Flamm, A Simon Lynch

  • 1Janssen Research & Development, 1000 Route 202, Raritan, NJ 08869, USA. tdavies1@its.jnj.com

Insights

Ceftobiprole demonstrates increased activity against ceftriaxone-resistant Streptococcus pneumoniae. Genetic analysis reveals penicillin-binding protein (PBP) mutations are key drivers of ceftriaxone resistance, though other mechanisms may exist.

Area of Science:

  • Microbiology
  • Genetics
  • Pharmacology

Background:

  • The Tracking Resistance in the US Today (TRUST) 2008 surveillance data indicated significant non-susceptibility to ceftriaxone in Streptococcus pneumoniae.
  • A notable percentage of these ceftriaxone-non-susceptible isolates exhibited high-level resistance, necessitating further investigation into resistance mechanisms and alternative treatment options.

Purpose of the Study:

  • To evaluate the activity of ceftobiprole against ceftriaxone-resistant Streptococcus pneumoniae isolates.
  • To characterize the genotypic traits, specifically mutations in penicillin-binding protein (PBP) and murM genes, associated with ceftriaxone resistance.

Main Methods:

  • Genomic DNA was extracted from 30 Streptococcus pneumoniae isolates with ceftriaxone minimum inhibitory concentrations (MICs) ≥ 8 μg/mL.
  • Sequencing of pbp1a, pbp2b, and pbp2x genes was performed to identify mutations and PBP patterns.
  • MurM alleles were analyzed to assess their association with resistance levels.

Main Results:

  • Nine distinct PBP patterns were identified among the isolates. The most common pattern involved specific substitutions in PBP1a, PBP2b, and PBP2x.
  • Ceftobiprole exhibited 4-16-fold greater activity than ceftriaxone against the tested ceftriaxone-resistant isolates.
  • While most isolates had wild-type or mosaic murM alleles, seven isolates with higher ceftriaxone resistance (MICs 8-32 μg/mL) possessed fewer PBP active-site motif substitutions, suggesting potential alternative resistance mechanisms.

Conclusions:

  • Widely identified PBP and MurM substitutions are likely responsible for high-level ceftriaxone resistance in most isolates.
  • The presence of fewer PBP substitutions in some highly resistant isolates suggests the involvement of additional or distinct resistance mechanisms contributing to high-level beta-lactam resistance.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...